hepat
b
viru
hbv
infect
major
global
health
problem
currentlyavail
therapi
ineffect
cure
chronic
hbv
infect
hbv
satellit
hepat
viru
hdv
infect
hepatocyt
via
bind
domain
larg
envelop
protein
sodium
taurochol
cotransport
polypeptid
ntcp
develop
novel
human
monoclon
antibodi
block
engag
ntcp
neutral
hbv
hdv
high
potenc
one
antibodi
function
picomolar
level
exhibit
neutralizationactivitymedi
prophylact
effect
also
act
therapeut
elicit
antibodyfcdepend
immunolog
effector
function
impos
durabl
suppress
viral
infect
hbvinfect
mice
result
reduct
level
small
envelop
antigen
viral
dna
emerg
escap
mutant
result
illustr
novel
antibodyfcdepend
approach
hbv
treatment
suggest
novel
clinic
candid
hbv
prevent
treatment
chronic
hbv
infect
human
hepat
b
viru
hbv
infect
peopl
hepat
c
viru
hcv
human
immunodefici
viru
hiv
combin
world
health
organ
despit
fact
effect
prophylact
hbv
vaccin
million
peopl
chronic
infect
hbv
carrier
high
risk
develop
sever
liver
diseas
rang
chronic
hepat
insuffici
cirrhosi
hepatocellular
carcinoma
hcc
world
health
organ
schweitzer
et
al
current
therapi
inadequ
treat
chronic
hbv
infect
exampl
immunemodulatori
interferon
alpha
therapi
cur
effect
small
portion
patient
nucleo
ide
analog
nuc
therapi
suppress
viral
replic
hardli
achiev
sustain
virolog
control
treatment
withdraw
noncur
lok
et
al
addit
problem
involv
coinfect
hepat
viru
hdv
satellit
viru
propag
presenc
hbv
approxim
million
hbv
carrier
coinfect
hdv
acceler
diseas
progress
exacerb
diseas
sever
effect
therapi
current
avail
hbv
patient
coinfect
hdv
antivir
therapi
specif
target
hdv
rizzetto
hugh
et
al
thoma
et
al
hbv
small
envelop
dna
viru
relax
circular
genom
upon
enter
hepatocyt
hbv
coval
close
circular
dna
cccdna
gener
nucleu
infect
cell
cccdna
serv
intermedi
viral
replic
viral
persist
reservoir
believ
cure
chronic
hepat
b
chb
would
requir
either
elimin
perman
silenc
cccdna
hepatocyt
andor
elimin
infect
hepatocyt
carri
cccdna
zeisel
et
al
seeger
mason
liang
et
al
block
et
al
gane
immunotherapi
base
human
monoclon
antibodi
mab
achiev
remark
clinic
success
treat
multipl
cancer
variou
autoimmun
inflammatori
diseas
recent
effort
shown
chronic
viral
infecti
diseas
treat
via
mabbas
immunotherapi
studi
report
promis
clinic
outcom
use
mab
broad
potent
activ
neutral
hiv
scheid
et
al
caskey
et
al
neutral
antibodi
nab
addit
capac
specif
block
viral
entri
via
fab
fragment
antigen
bind
recognit
viru
found
exert
varieti
immunolog
effector
function
includ
clearanc
circulatori
virus
well
mediat
cytotox
kill
phagocytosi
infect
cell
dilillo
et
al
corti
et
al
bournazo
et
al
bruel
et
al
lu
et
al
hessel
et
al
even
possibl
trigger
sustain
host
immun
respons
vivo
pelegrin
et
al
exampl
cancer
cell
virusinfect
cell
elimin
antibodi
depend
cellmedi
cytotox
adcc
phagocytosi
adcp
interact
fc
fragment
crystalliz
domain
antibodi
cognat
fcg
receptor
fcgr
express
immun
cell
therefor
although
result
immunebas
therapi
treat
hbv
far
disappoint
novel
nabbas
immunotherapi
may
repres
new
modal
cure
chronic
hbv
infect
infect
hbv
mediat
hbv
envelop
protein
main
target
neutral
antibodi
structur
data
avail
multitransmembran
protein
larg
l
envelop
protein
hbv
domain
ntermin
end
domain
play
pivot
role
hbv
hdv
infect
le
seyec
et
al
blanchet
sureau
figur
supplement
discov
domain
l
protein
specif
bind
liver
bile
acid
transport
sodium
taurochol
cotransport
polypeptid
ntcp
hepatocyt
thusli
mediat
viral
entri
hbv
hdv
yan
et
al
li
given
key
function
role
domain
contain
ntcpbind
site
attract
target
develop
nab
hbv
hdv
infect
present
studi
took
advantag
larg
nonimmun
phage
display
human
antibodi
librari
human
ntcpenabl
hbv
cell
cultur
system
yan
et
al
sun
et
al
identifi
panel
nab
specif
target
domain
one
lead
nab
show
strong
neutral
abil
hdv
hbv
use
crystallograph
studi
identifi
epitop
sequenc
analysi
predict
epitop
highli
conserv
eight
ten
hbv
genotyp
neutralizationori
optim
lead
nab
antibodi
engin
result
potent
nab
picomolar
neutral
activ
major
epidem
genotyp
hbv
b
c
importantli
demonstr
adcc
activ
natur
killer
nk
cell
macrophag
adcp
activ
macrophag
vitro
anim
studi
prophylact
use
result
full
protect
human
mice
hdv
hbv
infect
moreov
greatli
reduc
hbv
infect
treatment
mous
model
studi
fc
mutant
anim
reveal
fcmediat
immun
effector
function
larg
respons
therapeut
effect
identif
human
nab
domain
hbv
l
protein
structur
analysi
antigenantibodi
complex
identifi
nab
block
viral
infect
use
peptid
deriv
domain
hbv
l
protein
figur
supplement
target
select
larg
nonimmun
phage
display
antibodi
librari
employ
cellbas
vitro
hbv
infect
system
identifi
six
nab
effect
neutraliz
hbv
differ
potenc
figur
epitop
map
direct
bind
competit
elisa
assay
show
nab
recogn
four
uniqu
epitop
repres
mge
presenc
test
ab
secret
hbeag
hbsag
level
sampl
supernat
measur
day
post
infect
dpi
hbv
neutral
activ
present
percentag
inhibit
secret
hbeag
hbsag
calcul
normal
infect
read
inhibit
b
neutral
hdv
infect
cell
cell
infect
mge
hdv
presenc
test
nab
match
isotyp
control
ab
dpi
hdv
delta
antigen
stain
fitcconjug
mab
cell
nuclei
stain
dapi
c
crystal
structur
scfv
complex
peptid
shown
ribbon
residu
genotyp
c
shown
stick
carbon
atom
color
cyan
vh
magenta
vl
yellow
peptid
oxygen
atom
color
red
nitrogen
atom
color
blue
interact
shown
ribbon
epitop
select
cdr
side
chain
shown
stick
view
perpendicular
panel
c
dot
line
denot
hydrogen
bond
e
surfac
view
peptid
bind
pocket
colorcod
orient
panel
f
protect
hntcptg
mice
hdv
infect
human
ntcptg
homozygot
background
ip
administ
mgkg
n
pb
control
n
day
birth
one
hour
later
mous
challeng
genom
equival
ge
hdv
mice
sacrif
dpi
hdv
total
rna
titer
left
yaxi
hntcp
transgen
express
right
yaxi
liver
tissu
measur
qpcr
horizont
dot
line
indic
reliabl
figur
continu
next
page
respect
figur
supplement
neutral
potenc
nab
correl
locat
epitop
relat
receptor
bind
site
rb
epitop
closer
cterminu
rb
show
potent
neutral
activ
compar
two
nab
includ
epitop
close
nterminu
rb
recogn
nonmyristoyl
peptid
epitop
distant
cterminu
rb
although
four
nab
similar
bind
activ
also
abl
neutral
hdv
infect
cell
figur
slightli
potent
neutral
hbv
hdv
select
character
optim
better
understand
structur
basi
bind
solv
crystal
structur
scfv
form
singlechain
fragment
variabl
domain
vhlinkervl
complex
peptid
correspond
residu
genotyp
c
figur
supplement
scfv
peptid
coexpress
e
coli
copurifi
cocrystal
complex
structur
determin
molecular
replac
refin
resolut
rfactor
rfree
valu
tabl
complex
structur
residu
peptid
show
wellord
electron
densiti
model
peptid
adopt
ushap
conform
situat
pocket
form
five
complementaritydeterminingregion
cdr
loop
variabl
heavi
vh
light
chain
vl
figur
e
interfac
scfv
peptid
buri
solvent
access
area
account
total
peptid
surfac
area
heavi
chain
light
chain
contribut
buri
surfac
area
respect
five
cdr
loop
involv
direct
bind
peptid
interact
interfac
includ
contribut
type
noncoval
interact
figur
tabl
eight
model
residu
except
gli
interact
directli
buri
surfac
mainli
involv
heavi
chain
interact
asp
residu
electrostat
interact
arg
loop
addit
arg
loop
form
hydrogen
bond
mainchain
carbonyl
oxygen
ala
phe
larg
hydrophob
benzyl
group
insert
deep
hydrophob
pocket
form
ala
arg
tyr
backbon
atom
phe
alon
contribut
buri
surfac
area
peptid
ala
ala
form
weak
hydrophob
interact
respect
tyr
met
expos
surfac
primarili
contact
light
chain
pro
form
hydrophob
interact
tyr
tyr
addit
asn
ser
make
sever
van
der
waal
contact
tyr
tyr
next
verifi
key
bind
residu
deduc
crystal
structur
complex
wildtyp
synthes
peptid
could
effici
compet
fulllength
peptid
bind
howev
three
variant
peptid
key
residu
asp
pro
phe
mutat
alanin
fail
compet
fulllength
peptid
bind
figur
supplement
alanin
substitut
leu
immedi
adjac
region
peptid
also
reduc
bind
competit
activ
indic
residu
involv
bind
note
sequenc
align
show
epitop
highli
conserv
among
hbv
genotyp
figur
figur
continu
detect
limit
copi
number
shown
yax
ng
total
liver
rna
sampl
squar
repres
one
mous
squar
color
indic
data
mous
doi
http
follow
sourc
data
figur
supplement
avail
figur
sourc
data
data
figur
doi
http
figur
supplement
hbv
envelop
protein
amino
acid
sequenc
align
peptid
doi
http
figur
supplement
bind
six
nab
peptid
character
epitop
doi
http
supplement
indic
potenti
provid
broad
protect
vast
major
hbv
genotyp
although
residu
epitop
variabl
among
differ
hbv
genotyp
eg
gli
genotyp
c
ly
arg
genotyp
figur
figur
supplement
mutat
peptid
effect
bind
figur
supplement
consist
observ
complex
structur
gli
make
direct
contact
gener
potent
nab
evalu
neutral
activ
vivo
employ
de
novo
hdv
infect
mous
model
recent
establish
et
al
transgen
express
human
ntcp
hntcptg
mous
liver
support
acut
hdv
infect
mediat
hbv
envelop
protein
use
model
prophylact
administr
hr
hdv
viral
challeng
result
one
log
reduct
viral
titer
mous
liver
compar
untreat
control
figur
nevertheless
treatment
abl
complet
block
hdv
infect
mous
liver
even
mgkg
dose
thu
increas
neutral
activ
preserv
conserv
epitop
need
yield
potent
broadlyneutr
antibodi
improv
vivo
efficaci
end
employ
variou
antibodi
engin
approach
includ
chain
shuffl
structureguid
design
cdrfocus
mutagenesi
vh
chain
shuffl
approach
fruit
identifi
improv
nab
vh
chain
shuffl
fix
variabl
light
vl
chain
pair
repertoir
naturallyoccur
variabl
heavi
vh
gene
led
identif
ab
higher
bind
affin
hbv
hdv
neutral
assay
perform
rank
neutral
abil
ab
rel
potent
broadlyneutr
nab
hbv
infect
act
block
bind
hbv
receptor
ntcp
competit
elisa
assay
show
almost
peptid
competit
pattern
mutat
affect
bind
activ
indic
target
epitop
figur
supplement
epitop
close
proxim
overlap
receptor
ntcpbind
site
figur
supplement
test
whether
neutral
activ
attribut
competit
bind
ntcp
use
stabl
cell
clone
express
high
level
hntcp
support
bind
fluorescentlabel
peptid
immunofluoresc
stain
assay
show
inhibit
bind
fitclabel
cell
dosedepend
manner
wherea
isotypematch
control
ab
figur
result
indic
neutral
mechan
like
involv
block
viral
entri
interf
bind
ntcp
probabl
owe
steric
hindranc
near
receptor
bind
site
next
examin
potenc
breadth
neutral
hbv
hdv
hbv
known
genotyp
differ
least
dna
sequenc
level
sunbul
genotyp
b
c
repres
major
epidem
genotyp
potent
neutral
three
genotyp
figur
also
compar
potenc
agent
known
block
hbv
entri
includ
commerci
hbig
hepat
b
immun
globulin
human
mous
mab
chi
et
al
two
prototyp
peptid
myrcludexb
bogomolov
et
al
ntcpbind
synthet
myristoyl
lipopeptid
genotyp
genotyp
c
assay
use
cellbas
hbv
infect
system
show
stronger
neutral
activ
hbig
infect
recombin
hbv
figur
hdv
figur
well
infect
six
hbv
primari
isol
deriv
hbvinfect
patient
genotyp
c
hbv
stronger
antihbv
activ
either
figur
consist
primari
human
hepatocyt
phh
infect
system
show
similar
neutral
potenc
clinic
viral
isol
hbvinfect
patient
genotyp
b
figur
examin
variat
epitopeform
amino
acid
sequenc
among
hbv
genotyp
assess
breadth
neutral
activ
hbv
addit
aforement
variabl
posit
posit
also
exhibit
heterogen
genotyp
f
h
leucin
posit
genotyp
alanin
figur
supplement
analysi
use
hbvdb
databas
reveal
leucin
mutat
present
low
frequenc
among
report
hbv
sequenc
total
sequenc
hayer
et
al
almost
complet
limit
genotyp
f
h
figur
supplement
elisa
bind
assay
show
bound
weakli
peptid
variant
contain
epitopeform
sequnc
f
h
genotyp
hbv
figur
supplement
suggest
like
limit
efficaci
rare
genotyp
even
sequenc
analysi
show
epitop
highli
conserv
neutral
assay
result
clearli
show
neutral
three
major
epidem
genotyp
hbv
remark
potenc
given
reason
extrapol
like
neutral
vast
major
hbv
viru
strain
evalu
prophylact
efficaci
hdv
infect
recent
establish
geneedit
mous
model
residu
mntcp
replac
hntcp
counterpart
hbig
isotypematch
control
antibodi
administ
indic
dose
ntcp
geneedit
homozyg
fvb
mice
hr
prior
hdv
challeng
mgkg
dose
complet
block
hdv
infect
reduc
hdv
titer
liver
limit
detect
day
six
hdv
challeng
notabl
mgkg
mgkg
dose
reduc
hdv
titer
respect
contrast
even
high
dose
hbig
iu
kg
reduc
hdv
titer
still
insuffici
prevent
hdv
infect
figur
next
examin
prophylact
efficaci
hbv
infect
human
liver
chimer
mice
chimer
liver
gener
transplant
human
hepatocyt
fah
frg
tripl
knockout
mice
hfrg
mice
known
highli
suscept
hbv
infect
strom
et
al
bissig
et
al
azuma
et
al
test
vivo
efficaci
neutral
viral
challeng
prophylact
therapeut
administr
patientderiv
virus
chimer
mice
hfrg
mice
use
ip
administ
hbig
match
isotyp
control
ab
indic
concentr
day
birth
one
hour
later
mous
challeng
ge
hdv
sacrif
post
infect
day
liver
tissu
collect
mous
hdv
total
rna
level
edit
ntcp
gene
express
measur
qpcr
data
present
similarli
figur
b
schemat
diagram
illustr
hbv
challeng
bleed
antibodi
administr
schedul
mous
studi
five
anim
use
group
recipi
hfrg
mice
challeng
ge
hbv
genotyp
b
day
singl
dose
mgkg
ip
administ
one
day
viral
challeng
prophylaxi
biweekli
dose
mgkg
ip
administ
start
day
day
challeng
therapeut
hbig
iukg
treatment
use
control
experi
high
level
human
averag
human
serum
albumin
level
mgml
experi
also
includ
viru
infect
vehicl
ctrl
hbig
control
group
treatment
began
five
dpi
last
dpi
figur
secret
hbsag
well
hbv
dna
rna
level
virolog
marker
measur
period
serum
sampl
hbv
rapidli
robustli
replic
hfrg
mice
figur
infectiononli
control
group
serum
hbv
dna
rna
level
reach
copiesml
respect
hbsag
level
exceed
iuml
singl
administr
mg
kg
one
day
prior
hbv
challeng
complet
protect
mice
hbv
infect
indic
level
virolog
marker
serum
sampl
therapeut
biweekli
treatment
mgkg
greatli
reduc
virolog
marker
sera
compar
infectiononli
control
hbig
treatment
group
remark
end
experi
dpi
treatment
result
three
log
reduct
hbv
dna
rna
level
rel
two
control
group
figur
addit
human
albumin
level
alanin
aminotransferas
alt
activ
mous
serum
sampl
monitor
throughout
studi
period
signific
differ
treat
group
group
includ
vehicl
control
prophylaxi
hbig
control
group
figur
supplement
liver
tissu
collect
end
experi
use
immunohistochem
stain
ihc
hbsag
hbcag
southern
blot
viral
dna
cccdna
northern
blot
viral
rna
consist
serabas
measur
liver
tissu
prophylaxi
group
anim
detect
hbsag
hbcag
hbv
dna
cccdna
rna
infect
vehicl
control
hbig
treatment
group
strong
signal
marker
liver
tissu
treatment
greatli
reduc
hbsag
hbcag
almost
undetect
level
hbv
dna
rna
figur
encourag
therapeut
effect
observ
hfrg
mous
model
dissect
mechanismofact
determin
whether
viral
neutral
mediat
fab
sole
antivir
mechan
addit
effector
function
mediat
fc
region
may
involv
first
examin
effector
function
use
vitro
assay
human
nk
cell
macrophag
two
type
immun
effector
cell
capabl
mediat
adcc
adcp
nk
cell
primarili
express
fcgriiia
mediat
adcc
wherea
macrophag
express
class
fcgr
perform
adcc
adcp
braster
et
al
herter
et
al
bournazo
et
al
initi
test
whether
activ
nk
cell
induc
adcc
experi
use
vitro
adcc
assay
employ
human
natur
killer
cell
express
allel
fcgriiia
g
chain
fc
receptor
line
effector
klingemann
et
al
two
stabl
cho
cell
line
express
either
wild
type
wt
epitop
mutant
epitop
establish
cell
express
recombin
singletransmembran
protein
wt
fuse
transmembran
domain
vesicleassoci
membran
protein
effici
bind
use
target
cell
line
cell
carri
mutat
abolish
bind
use
control
cell
line
figur
supplement
isotypematch
control
antibodi
treatment
result
dosedepend
cytotox
effect
cell
effect
observ
control
cell
demonstr
nk
cellmedi
adcc
requir
presenc
epitop
target
cell
figur
confirm
adcc
activ
process
invari
requir
fcfcgr
interact
gener
variant
two
mutat
fc
region
ratio
adcc
activ
left
measur
describ
adcp
assay
right
target
cell
label
cfse
fluoresc
dye
prior
mix
macrophag
adcp
activ
monitor
fluoresc
microscopi
phagocytosi
index
determin
number
cfseposit
target
cell
per
macrophag
mean
error
bar
shown
two
independ
experi
cdc
activ
control
antibodi
rabbit
complement
sera
sigmaaldrich
use
sampl
test
triplic
rituximab
mab
posit
control
mab
assay
fc
region
human
data
shown
panel
b
repres
least
two
independ
experi
antibodi
test
mgml
panel
cd
doi
http
follow
sourc
data
figur
supplement
avail
figur
known
abolish
bind
fc
class
fcgr
shield
et
al
wilson
et
al
expect
variant
could
still
bind
cell
peptid
neutral
hbv
infect
extent
figur
supplement
could
bind
fc
receptor
reveal
fac
bind
assay
use
cell
spr
analysi
biacor
use
solubl
human
mous
fcgr
figur
figur
supplement
figur
supplement
consist
variant
could
induc
adcc
activ
figur
use
adcc
assay
also
demonstr
variant
caus
adcc
hbvinfect
cell
cell
infect
hbv
specif
kill
nk
cell
wherea
cell
uninfect
hbv
spare
nk
cell
kill
figur
next
examin
mediat
adcc
adcp
via
macrophag
fulli
differenti
human
macrophag
mix
target
cell
see
materi
method
express
epitop
surfac
adcp
adcc
observ
follow
treatment
wild
type
variant
figur
figur
figur
supplement
fac
analysi
confirm
bound
target
cell
similar
extent
figur
supplement
target
cell
express
mutant
epitop
specif
adcc
adcp
observ
figur
similar
result
obtain
use
mous
bone
marrowderiv
macrophag
bmdm
effector
cell
figur
supplement
taken
togeth
result
vitro
assay
suggest
kill
target
cell
via
fcfgr
interactiondepend
effector
function
adcc
adcp
analyz
activ
complement
induc
cdc
presenc
complement
sera
rabbit
human
caus
cell
lysi
cell
test
condit
rituximab
chimer
antibodi
known
caus
cdc
induc
targetspecif
cdc
figur
nakano
et
al
van
meerten
et
al
thu
compet
induc
cdc
target
cell
consist
weak
bind
activ
humanand
mous
figur
supplement
assess
whether
effector
function
contribut
vivo
efficaci
compar
antivir
activ
aforement
hdv
hbv
infect
mous
model
fc
human
isotyp
abl
engag
mous
fcgr
mous
effector
cell
figur
supplement
overdijk
et
al
ntcp
geneedit
homozyg
fvb
mice
show
similar
prophylact
efficaci
offer
complet
protect
hdv
infect
mgkg
dose
figur
result
suggest
fabmedi
neutral
rather
fcmediat
effector
function
primarili
respons
prevent
viral
infect
mous
model
support
transientlyacut
hdv
infect
thu
suitabl
assess
prophylact
efficaci
therefor
use
hfrg
mous
model
support
sustain
hbv
infect
determin
therapeut
effect
requir
fcfgr
interactiondepend
effector
function
hfrg
mice
medium
level
human
averag
human
serum
albumin
level
mgml
challeng
hbv
day
dpi
nine
mice
similar
level
stablyestablish
hbv
infect
divid
three
group
treat
mgkg
mgkg
pb
vehicl
control
treatment
administ
twice
weekli
total
week
figur
blood
collect
period
monitor
virolog
marker
includ
dna
titer
hbsag
level
end
experi
dpi
hbv
dna
titer
hbsag
level
increas
time
control
group
averag
dna
titer
ml
averag
hbsag
level
iuml
dpi
group
averag
hbv
dna
titer
hbsag
level
ml
iuml
respect
dpi
contrast
compar
control
group
treatment
group
reduct
dna
titer
ml
fold
reduct
hbsag
level
iuml
dpi
importantli
contrast
control
pb
treatment
result
reduct
hbv
dna
titer
hbsag
level
time
start
begin
treatment
continu
treatment
window
week
treatment
withdraw
slight
experi
perform
similarli
describ
figur
fc
mutant
test
mgkg
copi
number
shown
yax
ng
total
liver
rna
sampl
b
schemat
diagram
illustr
hbv
challeng
bleed
antibodi
treatment
schedul
mous
studi
figur
continu
next
page
rebound
end
experi
week
treatment
withdraw
figur
result
show
treatment
effici
suppress
spread
hbv
mice
could
also
gradual
reduc
extent
establish
hbv
infect
time
contrast
abl
suppress
spread
hbv
compar
control
group
reduc
extent
establish
hbv
infect
level
hbv
dna
hbsag
test
time
point
treatment
higher
start
point
treatment
note
treat
mice
compar
serum
antibodi
concentr
time
point
test
figur
compar
human
albumin
level
viral
challeng
dpi
figur
supplement
liver
tissu
collect
end
experi
use
ihc
stain
hbsag
southern
blot
viral
dna
cccdna
consist
serabas
measur
liver
tissu
mice
greatli
reduc
level
hbsag
ihc
assay
compar
control
mice
figur
figur
supplement
signific
histopatholog
chang
relat
treatment
observ
southern
blot
show
hbv
total
dna
cccdna
undetect
group
wherea
strong
total
dna
cccdna
signal
observ
control
group
figur
quantif
cccdna
level
liver
tissu
qpcr
independ
confirm
mice
inde
much
lower
cccdna
copi
number
two
group
figur
result
demonstr
potent
vivo
antivir
effect
moreov
comparison
effect
treatment
side
side
clearli
prove
antivir
effect
result
part
fabmedi
neutral
fcdepend
effector
function
particularli
critic
confer
overal
therapeut
effect
examin
hbv
escap
mutant
aris
select
pressur
treatment
sequenc
hbv
l
gene
amplifi
mous
liver
tissu
collect
end
two
figur
continu
three
anim
use
group
recipi
hfrg
mice
challeng
hbv
virus
genotyp
ge
twice
weekli
treatment
pb
mgkg
mgkg
began
dpi
last
week
c
hbv
dna
titer
hbsag
level
serum
blood
sampl
collect
indic
time
point
measur
hbv
dna
titer
andor
hbsag
level
antibodi
concentr
antibodi
concentr
serum
sampl
measur
elisa
use
antibodi
standard
known
concentr
note
dpi
dpi
blood
sampl
collect
three
day
ab
administr
dpi
blood
sampl
collect
hr
ab
administr
horizont
dot
line
indic
lowest
detect
limit
vertic
dot
line
greyshad
area
indic
treatment
window
cd
e
ihc
stain
human
hbsag
serial
section
liver
tissu
sacrif
hfrg
mice
end
experi
dpi
intrahepat
hbsag
detect
specif
antihbsag
mous
mab
follow
hrpantimous
secondari
ab
stain
brown
use
dab
substrat
nuclei
stain
blue
hematoxylin
human
hepatocyt
consecut
tissu
section
visual
stain
humanspecif
mab
dab
substrat
blue
violet
nuclei
stain
nuclear
fast
red
imag
shown
repres
stain
result
one
mous
group
f
southern
blot
analysi
intrahepat
viral
dna
total
hbv
dna
extract
mous
liver
tissu
dpi
extract
dna
sampl
analyz
southern
blot
dctplabel
fulllength
hbv
dna
probe
dna
sampl
prepar
normal
mous
liver
use
neg
control
pg
kb
kb
kb
hbv
dna
fragment
use
dna
marker
rcdna
relax
circular
dna
cccdna
ssdna
singlestrand
dna
intermedi
label
g
qpcr
quantif
intrahepat
viral
cccdna
level
ng
total
dna
prepar
liver
tissu
collect
dpi
digest
psad
digest
sampl
use
quantifi
hbv
cccdna
qpcr
use
specif
primer
see
materi
method
hntcp
gene
copi
number
repres
amount
human
hepatocyt
liver
tissu
chimer
mice
use
normal
cccdna
level
human
hepatocyt
sampl
cccdna
copi
number
shown
yaxi
rel
valu
normal
copi
hntcp
gene
ng
total
dna
sampl
squar
repres
one
mous
horizont
dot
line
indic
reliabl
detect
limit
aforement
studi
hfrg
mice
random
mutat
observ
within
l
gene
mous
studi
appear
mutat
treatment
group
control
group
mutat
specif
associ
treatment
mutat
found
within
antibodi
epitop
figur
supplement
although
complet
rule
possibl
treatment
may
induc
escap
mutant
result
indic
epitop
receptorbind
proxim
highli
conserv
region
center
phe
like
unsuscept
escap
mutat
highli
potent
direct
antivir
agent
chronic
hepat
c
hcv
cure
hcvinfect
patient
schreiber
et
al
feld
et
al
cure
hbv
thu
becom
next
major
goal
fight
viral
hepat
monoclon
antibodi
rapidli
becom
import
drug
class
especi
treat
cancer
autoimmun
diseas
howev
potenti
use
mab
treat
chronic
viral
infect
begin
explor
hbv
nab
hbv
small
envelop
protein
hbsag
constitut
major
protect
compon
widelyus
recombin
hbv
vaccin
postexposur
prophylact
bloodderiv
hbig
howev
neither
vaccin
hbig
effect
treat
persist
hbv
infect
tsuge
et
al
previou
studi
report
combin
two
monoclon
nab
hbsag
hepexb
exhibit
shortterm
antivir
effect
anim
model
earli
phase
human
studi
eren
et
al
neumann
et
al
human
antihbsag
nab
recent
shown
longer
antivir
effect
mous
model
mainli
clearanc
abhbsag
immun
complex
phagocytosi
high
level
circul
hbsagcontain
noninfecti
subvir
particl
commonli
present
blood
chronicallyinfect
hbv
patient
seeger
et
al
assum
hbsag
act
decoy
prevent
antihbsag
nab
effect
target
infecti
virion
infect
cell
format
circul
immun
complex
may
lead
immun
complex
diseas
also
remain
potenti
risk
compar
hbsag
l
protein
much
less
abund
circul
preferenti
present
infecti
hbv
particl
seeger
et
al
moreov
known
domain
l
protein
respons
receptor
ntcp
bind
yan
et
al
date
two
nab
murin
nab
human
nab
shown
abl
prevent
hbv
infect
inject
chimpanze
prior
hbv
challeng
chi
et
al
zhang
et
al
howev
neither
nab
test
treatment
establish
hbv
infect
mechanist
studi
conduct
nab
hbv
subtypespecif
nab
owe
sequenc
variat
epitop
residu
svpnp
recogn
residu
nsnnpdwdf
broader
neutral
activ
potenc
limit
diminish
promis
therapi
potent
viral
neutral
activ
low
picomolar
ic
valu
cell
cultur
consist
vitro
potenc
extrem
effect
protect
mice
de
novo
hdv
hbv
infect
remark
demonstr
impress
therapeut
efficaci
hbv
infect
two
independ
mous
studi
use
liverhuman
hfrg
mice
present
immunecompet
small
anim
model
support
natur
longlast
hbv
infect
although
hfrg
mice
immunodefici
azuma
et
al
model
recapitul
complet
life
cycl
hbv
valuabl
model
evalu
efficaci
antibodi
hbv
infect
vivo
initi
anim
studi
hfrg
mice
highlevel
human
chimer
liver
end
day
due
rampant
viral
propag
untreat
control
group
advers
effect
gener
health
mice
second
studi
slower
viral
propag
rate
like
due
mediumlevel
liver
human
andor
rel
lower
propag
rate
challeng
viru
last
day
allow
us
assess
antivir
effect
longer
period
monitor
infect
longer
experiment
period
reveal
mark
reduct
extent
establish
hbv
infect
mice
mechanist
found
viral
neutral
domin
mechan
contribut
protect
mice
hdv
infect
contrast
addit
protect
hepatocyt
viral
entri
fcmediat
effector
function
contribut
substanti
overal
antivir
effect
hbv
infect
hfrg
mice
experi
hfrg
model
reveal
wildtyp
fcdana
mutant
variant
incap
mediat
antibodydepend
effector
function
elicit
remark
antivir
effect
establish
hbv
infect
hfrg
mice
lack
b
lymphocyt
nk
cell
nk
cell
gener
consid
main
effector
cell
mediat
adcc
induc
apoptosi
target
cell
observ
effector
function
hfrg
model
thu
attribut
nk
cell
remain
immun
effector
cell
mice
exampl
fcgrexpress
macrophag
meloid
cell
eg
neutraphil
capabl
kill
infect
hepatocyt
adcc
andor
adcp
antibodydepend
scretion
antivir
cytokin
direct
clearanc
antibodyopson
virus
via
phagocytosi
consid
primari
hepatocyt
hbvinfect
hepatocyt
may
resist
cdc
halm
et
al
koch
et
al
liu
et
al
zhang
et
al
lack
complement
bind
activ
cdc
activ
vitro
cdc
unlik
involv
antivir
effect
hbvinfect
hfrg
mice
macrophag
previosuli
shown
major
effector
cell
invovl
antitumor
activ
sever
mab
mice
clyne
et
al
hamaguchi
et
al
minardcolin
et
al
macrophag
exert
cytotox
function
via
divers
mechan
adcc
adcp
etc
braster
et
al
neutrophil
also
report
involv
antitumor
efficaci
two
mab
tumor
model
mice
sider
et
al
golay
et
al
interest
identifi
immun
effector
cell
involv
mediat
vivo
antivir
effect
futur
studi
cell
involv
could
identifi
via
select
deplet
macropahg
van
rooijen
hendrikx
neutraphil
daley
et
al
use
specif
reagent
target
hfrg
mice
human
mechan
underli
hbv
control
partial
understood
har
immun
control
combat
chronic
hbv
infect
promis
remain
challeng
liang
et
al
block
et
al
zhang
et
al
guidotti
et
al
isorc
et
al
lucifora
et
al
bertoletti
rivino
bertoletti
ferrari
chronic
hbv
infect
appear
nk
cell
impair
secret
antivir
cytokin
eg
ifng
yet
abl
maintain
cytotox
maini
peppa
sun
et
al
shabani
et
al
proport
fcgrexpress
nk
cell
liver
total
nk
cell
liver
lower
blood
burt
et
al
nontheless
given
retain
cytotox
fcgrexpress
nk
cell
assum
adcc
activ
hepat
macropahg
includ
infiltr
macrophag
liverresid
macrophag
kupffer
cell
account
tissu
macrophag
entir
bodi
jenn
kube
role
cell
hbv
infect
appear
complic
ju
tack
similar
human
tumorassoci
macrophag
hepat
macropahg
like
retain
antibodydepend
effector
fuction
via
express
fcgr
herter
et
al
grugan
et
al
futur
human
clinic
trial
allow
us
determin
found
hfrg
mice
elicit
fcdepend
effect
function
via
activ
immun
cell
liver
exert
antivir
effect
two
aspect
antihbv
effect
worth
note
first
treatment
result
substanti
decreas
hbsag
level
blood
hbvinfect
hfrg
mice
time
serolog
hbsag
reduct
eventu
hbsag
loss
consid
critic
step
toward
function
cure
current
nuc
therapi
rare
reduc
hbsag
level
chb
patient
specif
target
vast
major
hbsag
particl
therefor
contrast
nab
target
hbsag
declin
hbsag
attribut
abmedi
clearanc
hbsag
blood
gradual
reduct
establish
hbv
infect
second
treatment
least
effect
suppress
cccdna
accum
like
reduc
cccdna
liver
tissu
due
techniquc
difficulti
quantifi
intrahepat
cccdna
treatment
began
howev
continu
reduct
level
dna
titer
hbsag
level
treatment
clearli
demonstr
reduc
extent
establish
hbv
infect
data
show
mediat
immun
effector
cell
kill
hbvinfect
cell
vitro
via
adcc
adcp
although
evdienc
need
conceiv
specul
clearanc
cccdnacarri
infect
cell
decreas
vivo
halfliv
fcdepend
effector
function
via
fcgr
engag
includ
cytotolyt
andor
noncytolyt
mechan
may
contribut
antihbv
effect
manner
beyond
fabmedi
blockag
new
infect
interest
determin
detail
mechan
antivir
effect
particular
rel
contribut
cytolyt
versu
noncytolyt
effect
process
summari
identifi
six
human
nab
phage
librari
improv
lead
hit
highaffin
broadspectrum
nab
extrem
potent
vitro
vivo
hdv
hbv
inhibit
ntcp
bind
recogn
structurallydefin
highlyconserv
epitop
locat
close
proxim
rb
also
capabl
trigger
epitopespecif
fcdepend
effector
function
importantli
effector
function
contribut
substanti
antivir
effect
hbv
infect
vivo
result
first
time
demonstr
nab
target
rb
adjac
region
exert
antihbv
effect
fcdepend
effector
function
engag
fcgr
point
toward
novel
antibodyfcdepend
strategi
hbv
treatment
human
embryon
kidney
cell
line
rrid
human
hepatocellular
carcinoma
cell
line
rrid
american
type
cultur
collect
atcc
manassa
va
human
hepatocellular
carcinoma
cell
line
rrid
raji
rrid
chines
hamster
ovari
cell
line
cho
rrid
cell
bank
type
cultur
collect
chines
academi
scienc
cell
line
use
hbv
hdv
vitro
neutral
assay
construct
previous
describ
cho
cell
line
cultur
dulbecco
modif
eagl
medium
dmem
supplement
fetal
bovin
serum
uml
penicillin
mgml
streptomycin
raji
cell
cultur
rpmi
medium
supplement
fetal
bovin
serum
uml
penicillin
mgml
streptomycin
cell
cultur
humidifi
incub
freestyl
cell
line
rrid
life
technolog
cell
cultur
follow
manufactur
instruct
cell
line
gener
provid
dr
zhang
li
beigen
establish
stabli
express
fcgriiia
allel
fcrg
chain
parent
cell
line
atcc
cell
line
use
studi
test
mycoplasma
test
neg
two
peptid
deriv
domain
hbv
genotyp
c
synthes
scilightpeptid
beij
china
puriti
greater
peptid
compris
residu
domain
hbv
l
protein
biotin
modif
cterminu
lipopeptid
compris
amino
acid
domain
biotin
modif
cterminu
myristoyl
modif
nterminu
human
nonimmun
scfv
singlechain
fragment
variabl
domain
vhlinkervl
antibodi
librari
construct
peripher
blood
mononuclear
cell
healthi
donor
use
select
synthes
peptid
briefli
peptid
captur
streptavidinconjug
magnet
dynabead
thermo
fisher
waltham
incub
phagescfv
particl
prepar
librari
peptid
two
round
select
perform
recov
highaffin
binder
magnet
bead
increas
divers
recov
phagescfv
two
elut
method
use
peptid
competit
elut
convent
basic
triethanolamin
solut
elut
subsequ
total
singl
clone
randomli
pick
rescu
produc
phagescfv
bacteri
cultur
supernat
clone
screen
specif
bind
andor
elisa
clone
screen
posit
one
peptid
clone
bound
andor
optic
densiti
nm
select
antibodi
gene
sequenc
gene
variabl
heavi
chain
vh
light
chain
vl
select
clone
sequenc
total
clone
uniqu
sequenc
identifi
clone
either
produc
purifi
phagescfv
particl
convert
fulllength
human
analyz
bind
peptid
elisa
evalu
hbv
andor
hdv
neutral
assay
end
top
six
clone
select
base
bind
hbvhdv
neutral
activ
prepar
purif
phagescfv
elisa
neutral
assay
phagescfv
supernat
ml
bacteri
cultur
precipit
concentr
pegnacl
sui
et
al
physic
particl
concentr
pegprecipit
phagescfv
quantifi
spectrophotometri
base
uv
absorpt
spectra
purifi
filament
phage
bind
viral
neutral
activ
differ
phagescfv
evalu
elisa
assay
cellbas
viral
neutral
assay
manner
similar
assay
use
fulllength
form
code
sequenc
vh
vl
scfv
subclon
respect
human
heavi
chain
hc
express
vector
light
chain
lc
express
vector
gener
fulllength
antibodi
cell
cotransfect
transient
two
express
plasmid
hc
lc
plasmid
ratio
day
transfect
cell
cultur
supernat
harvest
purif
via
protein
bead
affin
chromatographi
elisa
bind
assay
mgml
streptavidin
sigma
aldrich
st
loui
mo
phosphat
buffer
salin
pb
coat
onto
ubottom
plate
nunc
maxisorp
denmark
ml
per
well
incub
overnight
hr
biotinlabel
peptid
variou
concentr
pb
ml
per
well
captur
onto
plate
incub
hr
phagescfv
base
elisa
serial
dilut
phagescfv
pb
contain
nonfat
milk
ad
well
ml
per
well
specif
bound
phagescfv
detect
ad
hrpconjug
mous
antibodi
ge
healthcar
chicago
il
incub
hr
incub
step
elisa
plate
wash
six
time
pbst
solut
tween
contain
pb
volum
ml
wash
solut
per
well
per
wash
follow
hrpconjug
antibodi
incub
elisa
signal
develop
tmb
substrat
sigma
min
room
temperatur
reaction
stop
ad
ml
h
per
well
colorimetr
absorb
measur
nm
automat
subtract
refer
absorb
nm
use
micropl
reader
biorad
hercul
ca
fulllength
elisa
method
basic
describ
phagescfv
except
bound
antibodi
detect
hrpconjug
mous
antihuman
igg
fc
antibodi
piercethermo
fisher
scientif
waltham
competit
elisa
assay
perform
manner
similar
aforement
bind
elisa
assay
except
test
ab
incub
captur
peptid
antigen
presenc
competit
peptid
briefli
differ
short
peptid
serial
dilut
concentr
mix
nm
ngml
antibodi
ad
elisa
plate
compet
bind
ab
captur
peptid
elisa
plate
amino
acid
sequenc
correspond
aa
genotyp
c
coexpress
e
coli
complex
purifi
immobil
metal
ion
affin
chromatographi
use
ninta
agaros
bead
qiagen
germantown
md
follow
size
exclus
chromatographi
superdex
column
ge
healthcar
purifi
complex
concentr
crystal
use
hang
drop
vapor
diffus
method
mix
ml
protein
mgml
mm
trishcl
ph
mm
nacl
ml
reservoir
solut
contain
sodium
acet
ph
needleshap
crystal
appear
day
crystal
flash
cool
liquid
nitrogen
xray
diffract
data
collect
beamlin
shanghai
synchrotron
radiat
facil
process
otwinowski
minor
structur
determin
resolut
molecular
replac
phaser
mccoy
use
vh
vl
deriv
structur
herceptinfab
complex
pdb
jordan
et
al
start
model
initi
model
molecular
replac
refin
phenix
adam
et
al
manual
rebuilt
coot
emsley
cowtan
final
model
includ
residu
scfv
residu
peptid
rampag
analysi
show
residu
favor
region
residu
allow
region
lovel
et
al
recombin
hbv
virus
genotyp
hdv
virus
genotyp
envelop
produc
plasmid
transfect
cell
yan
et
al
sun
et
al
serum
deriv
hbv
virus
genotyp
b
c
deidentifi
blood
remnant
sampl
hbv
patient
neutral
assay
perform
previous
describ
yan
et
al
yan
et
al
minor
modif
hbv
infect
cell
cell
cultur
pmm
medium
yan
et
al
hr
plate
cellswel
plate
cellswel
prior
viral
infect
multipl
genom
equival
mge
hbv
mix
ab
inocul
cell
presenc
incub
hr
cell
wash
three
time
media
maintain
pmm
cell
cultur
medium
chang
fresh
pmm
medium
everi
day
first
medium
chang
seven
dpi
cultur
supernat
collect
test
hbvsecret
viral
antigen
hbsag
hbeag
commerci
elisa
kit
wantai
china
level
hbeag
andor
hbsag
use
evalu
hbv
neutral
activ
antibodi
data
normal
viru
infect
control
ic
valu
calcul
nonlinear
regress
curv
fit
use
graphpad
prism
six
softwar
hbv
neutral
assay
use
phh
cell
plasmaderiv
hbv
genotyp
b
use
neutral
assay
perform
plate
phh
cell
harvest
human
frg
mice
phh
cell
infect
mge
hbv
presenc
isotypematch
control
ab
hbig
variou
concentr
hr
infect
medium
chang
mainten
cultur
medium
cell
cultur
supernat
harvest
everi
day
measur
hbsag
level
hbsag
level
serum
sampl
determin
use
commerci
kit
china
hdv
infect
cell
infect
similarli
hbv
infect
mge
hdv
virus
ab
mix
virus
inocul
cell
seven
dpi
hdvinfect
cell
fix
methanol
room
temperatur
min
intracellular
delta
antigen
stain
mgml
fitcconjug
mous
antihdv
delta
antigen
monoclon
antibodi
nuclear
delta
antigen
stain
dapi
imag
captur
nikon
eclips
ti
fluoresc
microscop
zeiss
lsm
meta
confoc
microscop
neutral
activ
hdv
determin
base
stain
delta
antigen
amount
number
infect
cell
stain
intens
vl
gene
clone
phagemid
vector
contain
repertoir
nonimmun
vh
gene
deriv
healthi
donor
construct
librari
size
librari
select
done
similarli
describ
antibodi
librari
select
antibodi
one
round
select
perform
total
individu
clone
randomli
pick
screen
elisa
posit
clone
sequenc
identifi
ab
uniqu
sequenc
kinet
analys
mutant
bind
fcgr
perform
biacor
biacor
ge
healthcar
similarli
describ
fcgr
express
suspens
cell
purifi
immobil
metal
affin
chromatographi
use
tag
fuse
cterminu
fcgr
proteinag
pierc
thermo
fisher
coval
attach
individu
flow
cell
surfac
sensor
chip
amin
coupl
use
amin
coupl
kit
biacor
antibodi
optim
concentr
captur
chip
ensur
bind
occur
homogen
langmuir
interact
analyt
fcgr
inject
flow
cell
serial
dilut
concentr
buffer
inject
serv
neg
control
upon
complet
associ
dissoci
cycl
surfac
regener
mm
glycinehcl
solut
associ
rate
ka
dissoci
rate
kd
affin
constant
kd
calcul
use
evalu
softwar
low
affin
interact
start
fcgr
concentr
nm
wherea
highaffin
interact
nm
fitclabel
peptid
mix
control
ab
indic
concentr
ad
cell
final
concentr
mixtur
nm
incub
min
cell
wash
five
time
william
e
medium
dapicontain
mount
solut
ad
cell
imag
captur
zeiss
lsm
meta
confoc
microscop
cell
use
effector
cell
assay
cell
express
fcgriiia
allel
fcrgchain
two
type
cell
use
target
cell
cho
cell
line
stabli
express
epitop
hbvinfect
cell
construct
cell
line
express
plasmid
first
construct
insert
code
dna
ctermin
ct
extracellular
domain
gene
encod
singlepass
type
iv
transmembran
protein
nt
cytoplasm
side
membran
ct
extracellular
domain
contain
two
amino
acid
ad
ct
end
long
linker
express
plasmid
transfect
cho
cell
follow
fac
sort
posit
popul
obtain
stabl
cell
line
mutant
stabl
cell
line
similarli
establish
use
neg
control
cell
line
adcc
adcp
assay
mutant
knock
bind
mab
recogn
mutant
form
use
fac
sort
mutant
express
cell
hbvinfect
cell
cell
infect
hbv
day
use
adcc
assay
adcc
assay
target
cell
wash
resuspend
rpmi
fb
medium
plate
cellswel
ubottom
plate
incub
briefli
variou
concentr
effector
cell
ad
cellswel
result
raito
e
well
contain
target
cell
antibodi
incub
hr
cytolysi
determin
lactat
dehydrogenas
ldh
releas
follow
instruct
cytotox
nonradioact
cytotox
assay
kit
promega
fitchburg
wi
percentag
cytotox
calcul
follow
manufactur
instruct
adcc
adcp
human
macrophag
human
pbmc
differenti
ngml
macrophag
colonystimul
factor
mcsf
peprotech
rocki
hill
nj
day
use
effector
macrophag
suspens
cell
use
target
cell
adcc
adcp
assay
cell
similarli
establish
except
stabl
transfect
transientlytransfect
cell
harvest
use
target
cell
hr
transient
transfect
assay
target
cell
cellswel
incub
mgml
rt
min
ad
differenti
macrophag
cellswel
result
e
ratio
hr
adcc
cytolysi
determin
lactat
dehydrogenas
ldh
releas
follow
instruct
cytotox
nonradioact
cytotox
assay
kit
adcp
target
cell
label
cfse
accord
manufactur
protocol
life
technolog
prior
incub
antibodi
phagocytosi
cfselabel
target
cell
macrophag
record
zeiss
pascal
confoc
system
phagocyt
index
determin
number
cfseposit
cell
per
macrophag
macrophag
count
per
sampl
prepar
mous
bone
marrowderiv
macrophag
bmdm
mous
bone
marrow
cell
flush
syring
tibia
femur
mice
dmem
medium
cell
collect
wash
pb
filter
mm
cell
strainer
differenti
cell
bmdm
resuspend
dmem
medium
supplement
secret
granulocytemacrophag
colonystimul
factor
gmcsf
englen
et
al
cell
cultur
medium
cultur
day
without
replenish
chang
medium
suspens
cell
use
target
cell
label
cfse
differenti
bmdm
label
dilut
antimous
thermo
fisher
clone
prior
incub
target
cell
cfse
label
target
cell
plate
densiti
cellswel
incub
mgml
rt
min
ad
differenti
label
bmdm
cellswel
result
e
ratio
hr
phagocytosi
cfselabel
target
cell
macrophag
record
nikon
confoc
microscop
target
cell
wash
resuspend
rpmi
medium
without
fb
contain
test
antibodi
mgml
plate
ubottom
plate
cellswel
complement
sera
deriv
rabbit
human
sigmaaldrich
ad
well
contain
target
cell
antibodi
final
sera
concentr
hr
rabbit
serum
hr
human
serum
incub
supernat
well
recov
detect
ldh
releas
use
cytotox
nonradioact
cytotox
assay
kit
promega
cytolysi
calcul
follow
instruct
kit
rituximab
use
system
posit
control
rituximab
commerci
antibodi
use
clinic
treat
lymphoma
chimer
antibodi
express
purifi
use
method
describ
fulllength
human
antibodi
capabl
induc
cdc
target
cell
nakano
et
al
van
meerten
et
al
fc
region
human
rituximab
prophylact
efficaci
studi
mutant
hdv
infect
mous
model
human
ntcp
human
ntcp
transgen
mice
hntcptg
use
evalu
ab
figur
ntcpedit
fvb
mice
residu
mntcp
replac
human
ntcp
counterpart
use
evalu
figur
compar
effect
figur
experi
homozygot
day
birth
use
anim
host
anim
facil
nib
beij
experi
conduct
follow
nation
guidelin
hous
care
laboratori
anim
perform
accord
institut
regul
approv
iacuc
nib
antibodi
indic
concentr
administr
hr
prior
hdv
viral
challeng
day
six
hdv
challeng
mice
sacrif
liver
tissu
harvest
frozen
liquid
nitrogen
immedi
liver
tissu
homogen
lyse
trizol
reagent
use
extract
total
rna
rna
sampl
revers
transcrib
cdna
prime
script
rtpcr
kit
takara
japan
cdna
obtain
ng
rna
sampl
use
templat
qpcr
quantifi
number
total
hdv
rna
hntcp
mrna
copi
abi
fast
real
time
system
instrument
appli
biosystem
waltham
et
al
gapdh
mrna
also
quantifi
use
intern
refer
control
qpcr
assay
hdv
total
rna
qpcr
primer
tcttcctcggtcaacc
hntcp
transgen
qpcr
primer
forward
primer
backward
primer
gggagcagtcc
edit
chimer
mhntcp
qpcr
primer
forward
primer
ggtctttcggc
backward
primer
hdv
rna
ntcp
mrna
copi
calcul
standard
curv
gener
sampl
known
copi
number
mous
hbv
infect
model
previous
establish
use
frg
fah
tripl
knockout
mice
transplant
human
hepatocyt
bissig
et
al
hfrg
hfrg
mice
gener
commerci
yecuri
tualatin
describ
previous
bissig
et
al
figur
figur
figur
supplement
studi
carri
facil
wuxi
apptec
use
approv
iacuc
protocol
human
hepatocyterepopul
frg
mice
serum
human
albumin
level
around
mgml
use
hbv
challeng
hbv
viru
genotyp
b
hbeag
neg
obtain
hbvinfect
patient
plasma
sampl
written
consent
total
hfrg
mice
challeng
high
viral
dose
ge
hbv
virus
ml
per
mous
tail
vein
inject
day
anim
monitor
daili
basi
bodi
weight
chang
clinic
sign
viral
infect
durat
vivo
studi
prophylaxi
group
five
mice
inject
mgkg
singl
ip
administr
one
day
prior
hbv
viru
challeng
hbig
treatment
group
treatment
start
day
five
post
infect
last
day
hbig
administr
everi
three
day
ip
inject
mgkg
iukg
mgkg
respect
prophylaxi
treatment
model
blood
sampl
collect
differ
time
point
sampl
use
quantifi
viral
hbsag
hbv
dna
rna
copi
sera
mice
sacrif
end
experi
dpi
liver
tissu
mice
harvest
one
portion
liver
tissu
frozen
liquid
nitrogen
immedi
upon
harvest
use
analysi
hbv
dna
rna
cccdna
remain
portion
liver
sampl
fix
pfa
neutral
pb
paraffinembed
ihc
analysi
hbsag
hbcag
compar
effect
hbvinfect
hfrg
mice
figur
g
figur
figur
supplement
studi
carri
nib
anim
facil
accord
approv
iacuc
protocol
hfrg
mice
use
experi
purchas
yecuri
mice
serum
human
albumin
level
around
mgml
hbv
viru
genotyp
prepar
cell
sell
et
al
total
nine
hfrg
mice
challeng
high
viral
dose
mge
hbv
per
mous
tail
vein
inject
day
mice
monitor
daili
basi
bodi
weight
chang
clinic
sign
viral
infect
durat
vivo
studi
pb
administr
ip
start
day
post
infect
twice
week
day
n
group
antibodi
given
mgkg
blood
sampl
collect
period
dpi
use
quantifi
viral
hbsag
describ
hbv
dna
copi
sera
one
mous
pb
control
group
found
dead
undetermin
caus
dpi
exclud
blood
collect
liver
tissu
collect
end
experi
dpi
rest
eight
mice
euthan
dpi
liver
tissu
harvest
one
portion
liver
tissu
frozen
liquid
nitrogen
immedi
upon
harvest
use
analysi
hbv
viral
dna
remain
portion
liver
sampl
fix
pfa
neutral
pb
paraffinembed
ihc
analysi
hbsag
hbsag
level
mous
serum
sampl
measur
use
commerci
avail
kit
autobio
diagnost
co
serum
sampl
dilut
time
depend
hbsag
level
sampl
quantif
hbv
dna
copi
serum
sampl
ml
serum
dilut
ml
ddh
ad
naoh
sampl
mix
well
incub
min
ml
taken
use
qpcr
templat
qpcr
perform
sybr
premix
ex
taq
kit
takara
use
hbv
dna
specif
primer
forward
revers
use
abi
fast
realtim
system
instrument
appli
biosystem
viral
dna
copi
calcul
base
standard
curv
gener
sampl
known
copi
number
total
rna
extract
ml
serum
sampl
dilut
ml
nacl
solut
use
tianamp
viru
dnarna
kit
tiangen
extract
rna
treat
dnase
reversetranscrib
cdna
primescript
rt
kit
takara
ml
reaction
ml
cdna
use
templat
qpcr
describ
previous
yan
et
al
primer
hbvspecif
rna
chimer
mous
liver
fix
pfa
neutral
pb
paraffinembed
process
ihc
analysi
hbsag
hbcag
use
standard
ihc
protocol
figur
figur
figur
supplement
intrahepat
hbsag
hbcag
detect
use
specif
goat
polyclon
antihepat
b
viru
surfac
antigen
abcam
uk
rabbit
polyclon
antihepat
b
viru
core
antigen
dako
denmark
donkey
polyclon
secondari
antibodi
goat
iggh
l
ap
abcam
donkey
polyclon
secondari
antibodi
rabbit
iggh
l
hrp
abcam
respect
apr
substrat
kit
zhongshan
jinqiao
compani
china
immpact
dab
peroxidas
substrat
vector
laboratori
burlingam
ca
use
stain
figur
figur
figur
supplement
intrahepat
hbsag
detect
use
mous
mab
hepat
b
viru
surfac
antigen
clone
follow
hrp
conjug
antimous
boster
biolog
technolog
pleasanton
ca
dab
substrat
brown
kit
boster
use
develop
hbsag
stain
signal
nuclei
stain
hematoxylin
consecut
tissu
section
immunostain
use
humanspecif
mous
monoclon
antibodi
clone
dako
visual
human
hepatocyt
dab
substrat
blue
violet
kit
boster
use
develop
stain
signal
nuclei
stain
use
nuclear
fast
red
boster
approxim
mg
frozen
liver
tissu
ground
mortar
lyse
lysi
buffer
mm
tri
nacl
mm
edta
sd
ph
presenc
proteinas
k
qiagen
overnight
rnase
digest
cell
lysat
extract
twice
phenol
chloroform
isoamyl
alcohol
ph
extract
genom
dna
precipit
equal
volum
isopropanol
overnight
dna
pellet
wash
ethanol
dissolv
te
buffer
mm
trishcl
mm
edta
ph
digest
hindiii
neb
ipswich
analyz
southern
blot
dna
sampl
normal
mous
liver
prepar
well
use
neg
control
southern
blot
figur
figur
supplement
ng
prepar
dna
sampl
load
one
sampl
per
lane
separ
agaros
gel
transfer
posit
charg
nylon
membran
membran
probe
diglabel
fulllength
hbv
dna
detect
hbv
sequenc
membran
hybrid
detect
use
xray
film
figur
mg
prepar
dna
separ
agaros
gel
electrophoresi
transfer
onto
amersham
hybondn
membran
ge
healthcar
load
amount
sampl
normal
copi
number
hntcp
dna
quantifi
qpcr
dna
sampl
see
detail
method
section
quantif
hbv
cccdna
mous
liver
tissu
qpcr
southern
blot
hybondn
membran
crosslink
subsequ
probe
dctp
mci
perkin
elmer
label
hbv
genotyp
access
number
linear
fulllength
genom
dna
overnight
hybrid
perfecthyb
plu
hybrid
buffer
sigma
membran
wash
expos
carestream
xomat
bt
film
pg
kb
kb
kb
hbv
dna
fragment
prepar
pcr
amplif
plasmid
contain
copi
linear
hbv
genotyp
genom
use
dna
marker
cccdna
select
extract
use
proteinfre
hirt
method
hirt
previous
describ
modif
briefli
select
extract
hbv
cccdna
mg
frozen
liver
tissu
lyse
ml
lysi
buffer
room
temperatur
min
follow
addit
ml
kcl
incub
room
temperatur
overnight
lysi
buffer
supplement
proteinas
k
contain
mm
trishcl
ph
mm
edta
mm
nacl
sd
lysat
clarifi
centrifug
g
min
extract
phenol
phenol
chloroform
dna
precipit
equal
volum
isopropanol
final
dissolv
te
buffer
mm
tri
mm
edta
southern
blot
dna
sampl
separ
agaros
gel
transfer
nylon
membran
hybondn
use
standard
neutral
transfer
procedur
kb
kb
kb
hbv
fragment
dna
also
run
agaros
gel
serv
molecular
marker
membran
probe
diglabel
hbv
dna
probe
hybrid
carri
ml
hybrid
buffer
hr
prehybrid
overnight
hybrid
follow
min
wash
ssc
sd
room
temperatur
min
wash
ssc
sd
membran
incub
block
buffer
min
follow
min
incub
antibodi
solut
equilibr
detect
buffer
min
membran
rins
cdpstar
expos
xray
film
room
temperatur
quantif
hbv
cccdna
mous
liver
tissu
qpcr
hbv
cccdna
quantifi
qpcr
use
protocol
previous
describ
modif
briefli
frozen
liver
tissu
homogen
lyse
lysi
buffer
mm
tri
nacl
mm
edta
sd
ph
presenc
proteinas
k
qiagen
total
dna
extract
accord
standard
phenolchloroform
extract
protocol
ml
plasmidsaf
adenosin
triphosph
atp
depend
deoxyribonucleas
dnase
psad
epicentr
technolog
madison
wi
use
digest
ng
total
dna
ml
reaction
volum
incub
hr
remov
linear
genom
hbv
replic
intermedi
dna
reaction
incub
min
inactiv
dnase
ml
digest
dna
sampl
use
qpcr
templat
quantif
intrahepat
hbv
cccdna
copi
hbv
cccdna
specif
qpcr
primer
forward
revers
hntcp
gene
copi
number
repres
amount
human
hepatocyt
liver
tissu
chimer
mice
use
normal
rel
cccdna
amount
infect
cell
sampl
quantif
human
ntcp
gene
copi
ng
undigest
dna
sampl
use
human
ntcp
specif
primer
anneal
second
intron
hntcp
gene
forward
revers
amount
hbv
cccdna
hntcp
gene
copi
calcul
use
standard
curv
gener
standard
plasmid
known
copi
number
total
rna
isol
frozen
liver
tissu
use
trizol
reagent
mg
total
rna
per
sampl
separ
formaldehydeagaros
gel
blot
onto
posit
charg
nylon
membran
diglabel
probe
prepar
dig
rna
label
kit
roch
switzerland
hybrid
membran
wash
expos
xray
film
clone
sequenc
l
gene
hbv
total
genom
dna
isol
frozen
homogen
liver
tissu
collect
individu
mous
treatment
group
control
group
l
gene
amplifi
extract
dna
pcr
use
set
specif
primer
two
pcr
perform
sampl
pcr
product
clone
ta
clone
ta
clone
clone
randomli
pick
sequenc
l
gene
coordin
structur
factor
deposit
protein
data
bank
access
code
